Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

 IFXGLMGLM-IV
Number of Patients890530157
Female Gender, n (%)773 (86.8%)404 (76.2%)121 (77.0%)
Mean (SD) Age, years55.8 (13.5)57.7 (13.0)56.3 (12.3)
Mean (SD) Weight, Kg75.4 (19.22)76.8 (19.4)78.4 (21.8)
Positive Rheumatoid Factor, %68.4%60.4%58.6%
Disease duration, years
 Mean (SD)9.8 (9.98)8.0 (7.61)6.5 (8.76)
 Median6.04.96.0
Number of previous DMARDs
 Mean (SD)2.1 (1.41)2.3 (1.08)2.5 (0.97)
Previous Therapies, %
 DMARDs87.2%94.5%98.7%
 NSAIDs59.7%48.3%54.8%
 Corticosteroids47.9%52.8%46.5%
 Methotrexate70.4%84.7%92.4%
Concomitant Therapies, %
 DMARDs89.3%88.6%88.5%
 NSAIDs53.4%43.8%49.0%
 Corticosteroids36.9%33.0%28.7%
 Methotrexate71.1%67.4%68.2%
Bio-naive, %93.7%86.2%80.3%
DAS 28 CRPa5.3 (1.37)4.5 (1.2)4.1 (1.0)
DAS 28 ESRa5.7 (1.49)4.7 (1.40)4.4 (1.16)
TJCa12.3 (8.11)9.5 (7.0)9.2 (6.6)
SJCa10.4 (7.04)8.1 (5.7)6.7 (4.8)
PtGAa60.2 (24.12)56.8 (25.2)59.2 (25.2)
MDGAa6.4 (2.15)5.9 (2.2)5.2 (2.5)
HAQa1.6 (0.70)1.3 (0.7)1.3 (0.7)
Pain, VASa57.2 (23.99)55.2 (25.6)58.2 (28.0)
CRP, mg/La18.2 (23.42)15.4 (31.4)20.1 (37.4)
ESR, mm/hra32.2 (24.16)24.2 (20.6)26.4 (18.6)
Morning stiffness, mina65.3 (45.51)54.4 (43.8)60.3 (45.7)
  1. aMean (SD)